BT-11 were developed as a functional food(food supplements) for cognitive improvement. We continue to invest heavily on the development related to brain.
S100A9 is responsible for the neurodegeneration and cognitive dificits in TG2576 mice. Its knockout is a potential target for the pharmacological therapy of AD.
We are aiming to develop therapeutic medicines for neurodegenerative diseases ultimately. we will obviously be a global company to improve on wellfare of humans welfare.
K-stemcell Co., Ltd., specializes in research and development of therapeutic agents for diseases with damaged cells and incurable diseases and providing stemcell banking service.